American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism by Wendy Lim, Grégoire Le.

Slides:



Advertisements
Similar presentations
VTE Toolkit Chapter Five Venous Disease Coalition
Advertisements

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Pulmonary Embolism. Introduction  Pulmonary Embolism is a complication of underlying venous thrombosis, most commonly of lower extremities and rarely.
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,
Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline.
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)
Management of Deep Vein Thrombosis and Pulmonary Embolism by Jack Hirsh, and John Hoak Circulation Volume 93(12): June 15, 1996 Copyright © American.
Ahmed Mohamed Abd Elmajeed 99
Diagnosis of venous thromboembolism
Evidence Based and Cost Effective Guideline for DVT Triage
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
D-dimer and helical CT-PA based diagnostic algorithm for PE
Daniel J. Lindner, M. D. , James M. Edwards, M. D. , Edward S
Deep vein thrombosis outpatient pathway and ultrasound sensitivity
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
Uses of different D-dimer levels can reduce the need for venous duplex scanning to rule out deep vein thrombosis in patients with symptomatic pulmonary.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,
Edward C. Rosenow, M.D.  Mayo Clinic Proceedings 
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Ida Martinelli, Anthonie W. A. Lensing, Saskia.
Volume 141, Issue 2, Pages e351S-e418S (February 2012)
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Catheter-related deep venous thrombosis in children with hemophilia
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,
Genetic sequence analysis of inherited bleeding diseases
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.
Venous Thromboembolism with Chronic Liver Disease
Pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis: Safety and feasibility study  Ruth L. Bush, MD, Peter.
Symptomatic venous thromboembolism after femoral vein harvest
Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.
Diagnosis of Venous Thromboembolism
Venous Thromboembolism and Antithrombotic Therapy in Pregnancy
Activity of eltrombopag in severe aplastic anemia
Prospective implementation of an algorithm for bedside intravascular ultrasound-guided filter placement in critically ill patients  Christopher D. Killingsworth,
Clinical Features From the History and Physical Examination That Predict the Presence or Absence of Pulmonary Embolism in Symptomatic Emergency Department.
Carlos Aguilar, MD, Valentin del Villar, MD 
Venous Thromboembolism (VTE)
Venous Thromboembolic Complications of Lung Transplantation: A Contemporary Single-Institution Review  Charles F. Evans, MD, Aldo T. Iacono, MD, Pablo.
How I treat cancer-associated venous thromboembolism
Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb  Thomas Gremmel, MD, Cihan Ay,
Daniel J. Lindner, M. D. , James M. Edwards, M. D. , Edward S
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Volume 2(Supplement 1):1-3
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Plasma biomarker concentrations between study groups.
Five-year outcome study of deep vein thrombosis in the lower limbs
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,
by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
by Wendy Lim, Sara K. Vesely, and James N. George
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.
Volume 2(Supplement 1):39-41
Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.
Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.
Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
European Society of Cardiology guidelines for the diagnosis of a) clinically suspected high-risk pulmonary embolism (PE) and b) clinically suspected non-high-risk.
A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.
Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.
Volume 2(Supplement 1):4-7
Cold agglutinin disease
Presentation transcript:

American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism by Wendy Lim, Grégoire Le Gal, Shannon M. Bates, Marc Righini, Linda B. Haramati, Eddy Lang, Jeffrey A. Kline, Sonja Chasteen, Marcia Snyder, Payal Patel, Meha Bhatt, Parth Patel, Cody Braun, Housne Begum, Wojtek Wiercioch, Holger J. Schünemann, and Reem A. Mustafa BloodAdv Volume 2(22):3226-3256 November 27, 2018 © 2018 by The American Society of Hematology

Flowchart for recommendations 1a and b (diagnosis of PE for patients with low PTP/prevalence [≤5%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. ****If feasible. Flowchart for recommendations 1a and b (diagnosis of PE for patients with low PTP/prevalence [≤5%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. ****If feasible. CDR, clinical decision rule; US, ultrasound. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendations 2a and b (diagnosis of PE for patients with intermediate PTP/prevalence [∼20%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. ****If feasible. Flowchart for recommendations 2a and b (diagnosis of PE for patients with intermediate PTP/prevalence [∼20%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. ****If feasible. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendations 3a and b (diagnosis of PE for patients with high PTP/prevalence [≥50%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***In selected situations, negative CTPA may be sufficient to rule out PE. ****Serial proximal US if clinical PTP >50%. Flowchart for recommendations 3a and b (diagnosis of PE for patients with high PTP/prevalence [≥50%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***In selected situations, negative CTPA may be sufficient to rule out PE. ****Serial proximal US if clinical PTP >50%. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendation 4 (diagnosis of recurrent PE) Flowchart for recommendation 4 (diagnosis of recurrent PE). *Hemodynamically stable, nonpregnant patient. **Highly sensitive D-dimer. Flowchart for recommendation 4 (diagnosis of recurrent PE). *Hemodynamically stable, nonpregnant patient. **Highly sensitive D-dimer. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendations 5a and b (diagnosis of DVT for patients with low PTP/prevalence [≤10%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. Flowchart for recommendations 5a and b (diagnosis of DVT for patients with low PTP/prevalence [≤10%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. LE DVT, lower extremity deep vein thrombosis. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendations 6a and b (diagnosis of DVT for patients with intermediate PTP/prevalence [∼25%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. Flowchart for recommendations 6a and b (diagnosis of DVT for patients with intermediate PTP/prevalence [∼25%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendations 7a and b (diagnosis of DVT for patients with high PTP/prevalence [≥50%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. Flowchart for recommendations 7a and b (diagnosis of DVT for patients with high PTP/prevalence [≥50%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendation 8 (diagnosis of recurrent lower extremity DVT). *Hemodynamically stable, nonpregnant patient. **Highly sensitive D-dimer. Flowchart for recommendation 8 (diagnosis of recurrent lower extremity DVT). *Hemodynamically stable, nonpregnant patient. **Highly sensitive D-dimer. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendations 9a and b (diagnosis of upper extremity DVT for patients with unlikely PTP/low prevalence [10%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. Flowchart for recommendations 9a and b (diagnosis of upper extremity DVT for patients with unlikely PTP/low prevalence [10%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. UE DVT, upper extremity deep vein thrombosis. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology

Flowchart for recommendations 10a and b (diagnosis of upper extremity DVT for patients with likely PTP/high prevalence [40%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. Flowchart for recommendations 10a and b (diagnosis of upper extremity DVT for patients with likely PTP/high prevalence [40%]). *Hemodynamically stable, nonpregnant patient. **See other algorithms. ***Highly sensitive D-dimer. Wendy Lim et al. Blood Adv 2018;2:3226-3256 © 2018 by The American Society of Hematology